Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs

Domenico Bianco, P. Jane Armstrong, Robert J Washabau, VMD, PhD

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Glucocorticoids with or without other immunotherapy are the initial treatment of choice for dogs with severe immune-mediated thrombocytopenia (IMT). The majority of treated dogs will have improvements in platelet counts within 5 to 7 days of starting therapy, but complications from hemorrhage often occur before a response is seen. Human IV immunoglobulin (hIVIG) blocks Fc receptors on mononuclear phagocytic cells in dogs; it is used in people with idiopathic thrombocytopenic purpura. Hypothesis: The purpose of this study was to describe adverse effects and benefit of hIVIG in addition to conventional immunosuppressive therapy in dogs with severe IMT. Animals: Five client-owned dogs with severe primary IMT. Methods: Case series. The hospital database was searched for dogs with primary IMT treated with hIVIG. Results: No adverse effects were noted during or after hIVIG infusion in any treated dog. Over a 6-month follow-up, all dogs were clinically normal when using conventional immunosuppressive therapy. Human IVIG was administered 3 days after initiation of immunosuppressive therapy in 4 dogs, and, after 2 days, in 1 dog. In all dogs, the mean platelet counts preand 24 hours post-hIVIG infusion (0.28-0.76 g/kg) were 2,500/μL and 50,600/μL (62,750/μL for the 4 responders), respectively. One dog failed to respond as promptly to hIVIG (0.34 g/kg), and the platelet count increased to 66,000/μL after 9 days of immunosuppressive therapy. The mean duration of hospitalization post-hIVIG in all 5 dogs was 1.8 days (12 hours for responders), and the mean total length of hospitalization was 4.6 days (3.5 days for responders). Active hemorrhage resolved and no packed red blood cell transfusions were required after hIVIG infusion for responders. Conclusions and Clinical Importance: Human IVIG was well tolerated and appeared to be associated with rapid platelet count recovery and amelioration of clinical signs in most dogs with IMT.

Original languageEnglish (US)
Pages (from-to)694-699
Number of pages6
JournalJournal of veterinary internal medicine
Volume21
Issue number4
DOIs
StatePublished - Jul 1 2007

Fingerprint

Idiopathic Thrombocytopenic Purpura
thrombocytopenia
Intravenous Immunoglobulins
immunoglobulins
Dogs
dogs
immunosuppressive agents
blood platelet count
Immunosuppressive Agents
Platelet Count
Therapeutics
therapeutics
hemorrhage
Hospitalization
adverse effects
thrombocytopenic purpura
therapy dogs
Hemorrhage
Erythrocyte Transfusion
phagocytes

Keywords

  • Canine
  • Idiopathic thrombocytopenic purpura
  • Platelet
  • Prednisone
  • Vincristine

Cite this

Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. / Bianco, Domenico; Armstrong, P. Jane; Washabau, VMD, PhD, Robert J.

In: Journal of veterinary internal medicine, Vol. 21, No. 4, 01.07.2007, p. 694-699.

Research output: Contribution to journalArticle

@article{45738295479e40d197a00bbdf9e88ef2,
title = "Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs",
abstract = "Background: Glucocorticoids with or without other immunotherapy are the initial treatment of choice for dogs with severe immune-mediated thrombocytopenia (IMT). The majority of treated dogs will have improvements in platelet counts within 5 to 7 days of starting therapy, but complications from hemorrhage often occur before a response is seen. Human IV immunoglobulin (hIVIG) blocks Fc receptors on mononuclear phagocytic cells in dogs; it is used in people with idiopathic thrombocytopenic purpura. Hypothesis: The purpose of this study was to describe adverse effects and benefit of hIVIG in addition to conventional immunosuppressive therapy in dogs with severe IMT. Animals: Five client-owned dogs with severe primary IMT. Methods: Case series. The hospital database was searched for dogs with primary IMT treated with hIVIG. Results: No adverse effects were noted during or after hIVIG infusion in any treated dog. Over a 6-month follow-up, all dogs were clinically normal when using conventional immunosuppressive therapy. Human IVIG was administered 3 days after initiation of immunosuppressive therapy in 4 dogs, and, after 2 days, in 1 dog. In all dogs, the mean platelet counts preand 24 hours post-hIVIG infusion (0.28-0.76 g/kg) were 2,500/μL and 50,600/μL (62,750/μL for the 4 responders), respectively. One dog failed to respond as promptly to hIVIG (0.34 g/kg), and the platelet count increased to 66,000/μL after 9 days of immunosuppressive therapy. The mean duration of hospitalization post-hIVIG in all 5 dogs was 1.8 days (12 hours for responders), and the mean total length of hospitalization was 4.6 days (3.5 days for responders). Active hemorrhage resolved and no packed red blood cell transfusions were required after hIVIG infusion for responders. Conclusions and Clinical Importance: Human IVIG was well tolerated and appeared to be associated with rapid platelet count recovery and amelioration of clinical signs in most dogs with IMT.",
keywords = "Canine, Idiopathic thrombocytopenic purpura, Platelet, Prednisone, Vincristine",
author = "Domenico Bianco and Armstrong, {P. Jane} and {Washabau, VMD, PhD}, {Robert J}",
year = "2007",
month = "7",
day = "1",
doi = "10.1892/0891-6640(2007)21[694:TOSITW]2.0.CO;2",
language = "English (US)",
volume = "21",
pages = "694--699",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs

AU - Bianco, Domenico

AU - Armstrong, P. Jane

AU - Washabau, VMD, PhD, Robert J

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Background: Glucocorticoids with or without other immunotherapy are the initial treatment of choice for dogs with severe immune-mediated thrombocytopenia (IMT). The majority of treated dogs will have improvements in platelet counts within 5 to 7 days of starting therapy, but complications from hemorrhage often occur before a response is seen. Human IV immunoglobulin (hIVIG) blocks Fc receptors on mononuclear phagocytic cells in dogs; it is used in people with idiopathic thrombocytopenic purpura. Hypothesis: The purpose of this study was to describe adverse effects and benefit of hIVIG in addition to conventional immunosuppressive therapy in dogs with severe IMT. Animals: Five client-owned dogs with severe primary IMT. Methods: Case series. The hospital database was searched for dogs with primary IMT treated with hIVIG. Results: No adverse effects were noted during or after hIVIG infusion in any treated dog. Over a 6-month follow-up, all dogs were clinically normal when using conventional immunosuppressive therapy. Human IVIG was administered 3 days after initiation of immunosuppressive therapy in 4 dogs, and, after 2 days, in 1 dog. In all dogs, the mean platelet counts preand 24 hours post-hIVIG infusion (0.28-0.76 g/kg) were 2,500/μL and 50,600/μL (62,750/μL for the 4 responders), respectively. One dog failed to respond as promptly to hIVIG (0.34 g/kg), and the platelet count increased to 66,000/μL after 9 days of immunosuppressive therapy. The mean duration of hospitalization post-hIVIG in all 5 dogs was 1.8 days (12 hours for responders), and the mean total length of hospitalization was 4.6 days (3.5 days for responders). Active hemorrhage resolved and no packed red blood cell transfusions were required after hIVIG infusion for responders. Conclusions and Clinical Importance: Human IVIG was well tolerated and appeared to be associated with rapid platelet count recovery and amelioration of clinical signs in most dogs with IMT.

AB - Background: Glucocorticoids with or without other immunotherapy are the initial treatment of choice for dogs with severe immune-mediated thrombocytopenia (IMT). The majority of treated dogs will have improvements in platelet counts within 5 to 7 days of starting therapy, but complications from hemorrhage often occur before a response is seen. Human IV immunoglobulin (hIVIG) blocks Fc receptors on mononuclear phagocytic cells in dogs; it is used in people with idiopathic thrombocytopenic purpura. Hypothesis: The purpose of this study was to describe adverse effects and benefit of hIVIG in addition to conventional immunosuppressive therapy in dogs with severe IMT. Animals: Five client-owned dogs with severe primary IMT. Methods: Case series. The hospital database was searched for dogs with primary IMT treated with hIVIG. Results: No adverse effects were noted during or after hIVIG infusion in any treated dog. Over a 6-month follow-up, all dogs were clinically normal when using conventional immunosuppressive therapy. Human IVIG was administered 3 days after initiation of immunosuppressive therapy in 4 dogs, and, after 2 days, in 1 dog. In all dogs, the mean platelet counts preand 24 hours post-hIVIG infusion (0.28-0.76 g/kg) were 2,500/μL and 50,600/μL (62,750/μL for the 4 responders), respectively. One dog failed to respond as promptly to hIVIG (0.34 g/kg), and the platelet count increased to 66,000/μL after 9 days of immunosuppressive therapy. The mean duration of hospitalization post-hIVIG in all 5 dogs was 1.8 days (12 hours for responders), and the mean total length of hospitalization was 4.6 days (3.5 days for responders). Active hemorrhage resolved and no packed red blood cell transfusions were required after hIVIG infusion for responders. Conclusions and Clinical Importance: Human IVIG was well tolerated and appeared to be associated with rapid platelet count recovery and amelioration of clinical signs in most dogs with IMT.

KW - Canine

KW - Idiopathic thrombocytopenic purpura

KW - Platelet

KW - Prednisone

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=34547785609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547785609&partnerID=8YFLogxK

U2 - 10.1892/0891-6640(2007)21[694:TOSITW]2.0.CO;2

DO - 10.1892/0891-6640(2007)21[694:TOSITW]2.0.CO;2

M3 - Article

C2 - 17708388

AN - SCOPUS:34547785609

VL - 21

SP - 694

EP - 699

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 4

ER -